Browsing Tag
C3 glomerulopathy
6 posts
Why complement pathway competition in renal disease is intensifying around oral C5aR therapies
InflaRx N.V. is expanding izicopan across renal diseases as complement therapy competition intensifies. Discover what this means for nephrology markets.
How the VALIANT Phase 3 data may strengthen EMPAVELI’s nephrology market position
Find out how Sobi’s VALIANT Phase 3 data may reshape EMPAVELI’s nephrology market position and what it means for rare kidney disease growth.
Novartis wins FDA approval for Fabhalta, the first treatment for C3 glomerulopathy
Novartis secures FDA approval for Fabhalta, the first-ever treatment for C3G. Find out how this breakthrough impacts patients and investors.
Game-changer for kidney disease: Novartis’ Fabhalta wins FDA approval in record time
Novartis has reached a pivotal moment in the treatment of rare kidney diseases with the US Food and…
Sobi and Apellis Pharmaceuticals report promising results for pegcetacoplan in phase 2 NOBLE study
Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the…
Positive results for pegcetacoplan in C3 glomerulopathy treatment: A step forward in kidney disease research
Apellis Pharmaceuticals has unveiled significant findings from its Phase 2 DISCOVERY clinical trial, offering a ray of hope…